Author

M. Schenone

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Cell Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 4 Assay:proteomics· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:host-pathogen & immune response· 2 Organism:C. elegans· 1 Research Focus:cell signaling & trafficking· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

S. A. Carr· 3 shared A. Apffel· 2 shared A. D'Andrea· 1 shared A. G. Myers· 1 shared A. Gonzalez· 1 shared A. J. Bass· 1 shared A. Shen· 1 shared A. Tserniak· 1 shared

Activity by Year

2018-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

S. A. Carr

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

BCOR and BCORL1 mutations disrupt PRC1.1 repressive function in leukemia by unlinking the RING-PCGF1 enzymatic core from target genes

E. J. Schaefer, W. C. Wang, C. A. Meyer, P. Cejas, M. D. Gearhart, E. R. Adelman, I. Fares, A. Apffel, K. Lim, Y. Xie, C. J. Gibson, M. Schenone, H. M. Murdock, E. S. Wang, L. P. Gondek, , R. C. Lindsley

This study shows BCOR and BCORL1 mutations disrupt PRC1.1 function in leukemia by separating its enzymatic core from chromatin targets, leading to treatment resistance.

bioRxiv · Mar 8, 2021 · PreprintCancer Biology

Identification of a novel regulator of Clostridioides difficile cortex formation

M. H. Touchette, H. Benito de la Puebla, C. Alves Feliciano, B. Tanenbaum, M. Schenone, S. Carr, A. Shen

This paper identifies SpoVQ as a novel regulator of C. difficile cortex formation, showing it links cortex and coat formation and is essential for spore viability.

bioRxiv · Mar 3, 2021Microbiology

CBL mutations promote activation of PI3K/AKT signaling via LYN kinase

R. Belizaire, S. H. J. Koochaki, N. Udeshi, A. Vedder, L. Sun, T. Svinkina, C. Hartigan, C. Stanclift, M. Schenone, S. A. Carr, E. Padron, B. L. Ebert

The paper investigates how CBL mutations drive oncogenesis by enhancing LYN kinase activity and PI3K/AKT signaling, suggesting LYN inhibition as a therapeutic strategy.

bioRxiv · Apr 13, 2020 · PreprintCancer Biology

WRN Helicase is a Synthetic Lethal Target in Microsatellite Unstable Cancers

E. Chan, T. Shibue, J. McFarland, B. Gaeta, J. McPartlan, M. Ghandi, J. B. Liu, J.-B. Lazaro, N. Dumont, A. Gonzalez, A. Apffel, S. O. Ali, L. Leung, E. Roberts, E. Rizvochenko, , A. J. Bass

The paper identifies WRN helicase as a synthetic lethal target in microsatellite unstable cancers through CRISPR/Cas9 and RNAi screens, showing its essentiality in MSI cell lines.

bioRxiv · Dec 21, 2018Cancer Biology

Tetracyclines Modify Translation By Targeting Key Human rRNA Substructures.

J. D. Mortison, M. Schenone, J. A. Myers, Z. Zhang, L. Chen, C. Ciarlo, E. Comer, S. K. Natchiar, S. A. Carr, B. P. Klaholz, A. G. Myers

This study identifies tetracyclines as targeting human rRNA substructures, modifying translation and activating the ISR, which correlates with their anti-proliferative effects in cancer cells.

bioRxiv · Feb 1, 2018Cell Biology